Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

The U.S. has been adept at inventing The Next Big Thing but sometimes stumbles when it comes to exploiting it. From cars to ...

There are more foreign companies paying to license technology from the U.S. National Institutes of Health than companies ...

The good news is that if you're willing to put in a bit of effort, it's very possible to improve on your process to secure ...

Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...

Chinese biotechnology firms are seeing the wildest swings in months as investors struggle to assess the impact of a US push ...

European equities traded in the US as American depositary receipts were falling on Friday morning, down 1.5% to 1,436.90 on the S&P Europe Select ADR Index. From continental Europe, the gainers were ...

High CEACAM1 and low PDL1 expression in tumors, as well as their combination identified as potential biomarkers associated with improved overall ...

The interest rate cut expected this week has a potential double impact of opening financial options to emerging growth ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today ...